Source comparison
Receptor Mechanisms: Direct Agonism vs Secretagogue Activity
IGF-1 LR3 functions as a direct IGF-1 receptor agonist with a critical structural modification: the substitution of glutamic acid for arginine at position 3, combined with a 13-amino-acid N-terminal extension. This modification reduces binding affinity to IGF
This comparison does not assign a generated winner or score.
- IGF-1 LR3 functions as a direct IGF-1 receptor agonist with a critical structural modification: the substitution of glutamic acid for arginine at position 3, combined with a 13-amino-acid N-terminal extension. This modification reduces binding affinity to IGF binding proteins (IGFBPs) by approximately 100-fold compared to endogenous IGF-1, which normally circulates 99% bound to IGFBPs in vivo. The result is a compound with significantly higher bioavailability and a half-life extended from 12–15 hours (native IGF-1) to 20–30 hours. In receptor binding assays, IGF-1 LR3 binds to the IGF-1 receptor (IGF1R) with comparable affinity to native IGF-1 but remains in circulation longer, creating sustained receptor activation.
- Ipamorelin operates through an entirely different cascade. It's a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively binds to the growth hormone secretagogue receptor 1a (GHSR1a, the ghrelin receptor) located on somatotroph cells in the anterior pituitary. Binding triggers intracellular calcium release and activation of protein kinase C pathways, resulting in pulsatile GH secretion. The key distinction from earlier GH secretagogues: Ipamorelin does not stimulate ACTH, cortisol, or prolactin release at standard research doses. A selectivity confirmed in preclinical models published in the Journal of Endocrinology. The GH pulse then stimulates hepatic IGF-1 production over 6–8 hours, creating downstream anabolic signaling through the same IGF-1 receptors that IGF-1 LR3 activates directly.